Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Simultaneous measurement of tadehaginoside and its principal metabolite in rats by HPLC-MS/MS and its application in pharmacokinetics and tissue distribution study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Taylor & Francis Country of Publication: England NLM ID: 9812552 Publication Model: Print Cited Medium: Internet ISSN: 1744-5116 (Electronic) Linking ISSN: 13880209 NLM ISO Abbreviation: Pharm Biol Subsets: MEDLINE
    • بيانات النشر:
      Publication: [London] : Taylor & Francis
      Original Publication: Lisse, the Netherlands : Swets & Zeitlinger, c1998-
    • الموضوع:
      Chromatography, High Pressure Liquid/*methods ; Coumaric Acids/*pharmacokinetics ; Glucosides/*pharmacokinetics ; Tandem Mass Spectrometry/*methods; Animals ; Coumaric Acids/analysis ; Glucosides/analysis ; Male ; Rats ; Rats, Sprague-Dawley ; Reproducibility of Results ; Tissue Distribution
    • نبذة مختصرة :
      Context: Tadehaginoside, an active ingredient isolated from Tadehagi triquetrum (Linn.) Ohashi (Leguminosae), exhibited various biological activities. However, the pharmacokinetics and tissue distribution which affect tadehaginoside's therapeutic actions and application remain elusive.
      Objective: To clarify the metabolism of tadehaginoside in vivo .
      Materials and Methods: The pharmacokinetics and tissue distribution of tadehaginoside and its metabolite p -hydroxycinnamic acid (HYD) were investigated using LC-MS/MS. Pharmacokinetic parameters were determined in 10 Sprague-Dawley rats divided into two groups, the intravenous group (5 mg/kg) and the oral group (25 mg/kg). For the tissue-distribution study, 20 rats were intravenously given tadehaginoside (5 mg/kg) before the experiment ( n  = 4). Biological samples were collected before drug administration (control group) and after drug administration.
      Results: The linearity, accuracy, precision, stability, recovery and matrix effect of the method were well-validated and the results satisfied the requirements of biological sample measurement. Treatment with tadehaginoside via intragastric and intravenous administration, the calculated C max in rats was 6.01 ± 2.14 ng/mL and 109.77 ± 4.29 ng/mL, and T max was 0.025 ± 0.08 h and 0.08 h, respectively. The results indicated that the quick absorption of tadehaginoside was observed following intravenous administration, and tadehaginoside in plasma of rats with intragastric administration showed relatively low concentration may be due to the formation of its metabolite. Tissue-distribution study indicated that kidney and spleen were the major distribution organs for tadehaginoside in rats and there was no long-term accumulation in most tissues.
      Discussion and Conclusion: These results could provide clues for exploring the bioactivity of tadehaginoside based on its pharmacokinetic characteristics.
    • References:
      J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 15;1124:323-330. (PMID: 31271908)
      Free Radic Res. 2001 Dec;35(6):941-52. (PMID: 11811545)
      Commun Agric Appl Biol Sci. 2014;79(2):233-8. (PMID: 26084102)
      J Nat Prod. 2016 May 27;79(5):1249-58. (PMID: 27100993)
      J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Sep 15;1031:154-162. (PMID: 27491065)
      Inflammation. 2014 Aug;37(4):1006-14. (PMID: 24448843)
      Biomed Pharmacother. 2016 Dec;84:230-236. (PMID: 27662473)
      J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jun 1;991:13-20. (PMID: 25902051)
      Molecules. 2019 Jan 15;24(2):. (PMID: 30650546)
      Front Pharmacol. 2019 Jun 27;10:712. (PMID: 31316382)
      Cancer Chemother Pharmacol. 2018 Nov;82(5):887-898. (PMID: 30206658)
      J Mass Spectrom. 2016 Jan;51(1):69-78. (PMID: 26757074)
      Drug Metab Dispos. 2009 Dec;37(12):2290-8. (PMID: 19786509)
      Nat Prod Res. 2019 Mar;33(6):893-896. (PMID: 29199477)
      Metabolomics. 2019 Oct 4;15(10):135. (PMID: 31584114)
      J Agric Food Chem. 2000 Nov;48(11):5496-500. (PMID: 11087508)
      Life Sci. 2019 Dec 1;238:116965. (PMID: 31629762)
      BMC Pharmacol. 2007 Aug 06;7:9. (PMID: 17683602)
      Nat Prod Res. 2015;29(18):1723-7. (PMID: 25612052)
      Nat Prod Res. 2015;29(24):2287-90. (PMID: 25589148)
    • Contributed Indexing:
      Keywords: metabolic profile; method development and validation; p-Hydroxycinnamic
    • الرقم المعرف:
      0 (Coumaric Acids)
      0 (Glucosides)
      0 (tadehaginoside)
    • الموضوع:
      Date Created: 20211025 Date Completed: 20220204 Latest Revision: 20220427
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC8547841
    • الرقم المعرف:
      10.1080/13880209.2021.1990354
    • الرقم المعرف:
      34689683